MetaVia's DA-1726 Shows Promising Weight Loss and Lipid Benefits—Key Phase 1 Results to Be Presented at ObesityWeek 2025
Phase 1 Data Supports Once-Weekly Dosing and Early Efficacy for Obesity Treatment
MetaVia Inc. (NASDAQ: MTVA) is set to share new Phase 1 and pre-clinical data for its investigational obesity drug, DA-1726, at ObesityWeek 2025. The lead program is a novel, dual agonist targeting both the GLP-1 and glucagon receptors. According to MetaVia’s press release, DA-1726 has demonstrated a pharmacokinetic (PK) profile enabling convenient once-weekly dosing, as well as clinically meaningful reductions in weight and waist circumference—observed without the need for dose titration. Importantly, DA-1726 was well tolerated at all tested doses, and no serious adverse events or cardiovascular issues were observed.
Best-in-Class Weight and Lipid Results Distinguish DA-1726 from Peers
Results from the Phase 1 study show that, at the highest dose (32 mg), participants achieved an average weight loss of 4.3% over four weeks, with some losing as much as 6.3% from baseline. Waist circumference was reduced by up to 3.9 inches, and these benefits were maintained for two weeks after stopping the medication. Additionally, in pre-clinical obesity models, DA-1726 delivered lipid-lowering effects that outperformed competitors like pemvidutide and showed better weight loss than tirzepatide, even when subjects had similar food intake.
| Feature | DA-1726 Results | Comparator | Comparative Outcome |
|---|---|---|---|
| Average Weight Loss (Day 26) | 4.3% | Pemvidutide/Tirzepatide | Comparable or Better |
| Maximum Weight Loss | 6.3% | — | — |
| Waist Circumference Change | -3.9 in | — | — |
| Lipid Lowering | Superior (TC, LDL-C) | Pemvidutide/Tirzepatide | Superior |
| Dosing | Once weekly | — | Linear, dose-proportional |
| Half-Life | ~80 hours | — | Supports weekly regimen |
| Serious Adverse Events | None reported | — | — |
Safety and Convenience Drive Appeal in Obesity Market
DA-1726's safety profile stood out: gastrointestinal side effects were mild and short-lived, and the trial saw no participant dropouts or dose-limiting toxicities. Linear, dose-proportional PK and an approximately 80-hour half-life make it a strong candidate for convenient weekly dosing, reducing patient burden. Encouraged by these findings, MetaVia has extended its Phase 1 study to evaluate a higher, 48 mg dose for eight weeks, aiming for even greater long-term efficacy data.
Potential Competitive Edge in Obesity Drug Pipeline
What sets DA-1726 apart? Not only does it induce meaningful weight and waist reductions, but it also appears to improve lipid parameters more effectively than leading dual agonists. In mouse models, it drove more weight loss than tirzepatide with similar food intake, a signal of enhanced energy expenditure and potentially broader metabolic benefits. Unlike other options, DA-1726 also preserved lean mass and achieved improved lipid lowering compared to competitors—making it one to watch in the evolving landscape of obesity therapies.
Looking Ahead: Results from Higher Dose and Extended Studies Pending
Investors and researchers alike will be watching for results from the extended 48 mg cohort of the Phase 1 study later this year. As new data emerges from both the clinic and the lab, DA-1726’s profile as a potentially best-in-class dual agonist for obesity and related metabolic disorders is growing stronger. For those interested in deeper science or the competitive dynamics in obesity drug development, keeping an eye on MetaVia’s presentations at ObesityWeek 2025 could be insightful.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI